Back to Search
Start Over
A high-fidelity RNA-targeting Cas13 restores paternal Ube3aexpression and improves motor functions in Angelman syndrome mice
- Source :
- Molecular Therapy; July 2023, Vol. 31 Issue: 7 p2286-2295, 10p
- Publication Year :
- 2023
-
Abstract
- Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by loss of function mutations in maternally expressed UBE3A. No gene-specific treatment is available for patients so far. Although intact and transcriptionally active, paternally inherited UBE3Ais silenced by elongation of antisense long noncoding RNA UBE3A-ATSin neurons. Here, we demonstrated that RNA targeting of paternal Ube3a-ATSwith a high-fidelity CRISPR-Cas13 (hfCas13x.1) system could restore Ube3aexpression to similar levels as that of maternal Ube3ain the cultured mouse neurons. Furthermore, injection into lateral ventricles with neuron-specific hSyn1promoter-driven hfCas13x.1 packaged in adeno-associated virus (AAV-PHP.eb) could restore paternal Ube3aexpression in cortex and hippocampus of neonatal AS mice for up to 4 months after treatment. Behavioral tests showed that expression of paternal Ube3asignificantly alleviated AS-related symptoms, including obesity and motor function. Our results suggested that hfCas13x.1-mediated suppression of the Ube3a-ATSlncRNA potentially serves as a promising targeted intervention for AS.
Details
- Language :
- English
- ISSN :
- 15250016 and 15250024
- Volume :
- 31
- Issue :
- 7
- Database :
- Supplemental Index
- Journal :
- Molecular Therapy
- Publication Type :
- Periodical
- Accession number :
- ejs62297607
- Full Text :
- https://doi.org/10.1016/j.ymthe.2023.02.015